Model 1 | Model 2 | Model 3 | Model 4 | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Coef. | SE | HR | 95%CI | Coef. | SE | HR | 95%CI | Coef. | SE | HR | 95%CI | Coef. | SE | HR | 95%CI | |
Hyperlipidemia group | 1.0 (ref.) | |||||||||||||||
DM group | 1.090 | 0.319 | 3.01 | 2.14 to 4.21 | 0.811 | 0.238 | 2.24 | 1.58 to 3.18 | 0.811 | 0.238 | 2.24 | 1.58 to 3.18 | 0.858 | 0.251 | 2.37 | 1.66 to 3.39 |
Among DM patients | ||||||||||||||||
The follow-up period | ||||||||||||||||
Hyperlipidemia (yes/no) | 0.434 | 0.127 | 1.20 | 0.91 to 1.61 | 0.391 | 0.115 | 1.08 | 0.80 to 1.45 | 0.391 | 0.121 | 1.14 | 0.84 to 1.54 | 0.369 | 0.108 | 1.02 | 0.73 to 1.43 |
From 48-moth follow up onwards | ||||||||||||||||
Hyperlipidemia (yes/no) | 1.046 | 0.306 | 2.89 | 1.37 to 6.07 | 1.046 | 0.306 | 2.89 | 1.34 to 6.22 | 1.303 | 0.382 | 3.60 | 1.62 to 8.01 | 1.303 | 0.382 | 3.60 | 1.62 to 8.01 |
Among non-DM patients | ||||||||||||||||
Hyperlipidemia (yes/no) | 0.366 | 0.107 | 1.01 | 0.82 to 1.51 | −0.103 | 0.095 | 0.90 | 0.65 to 1.24 | −0.101 | 0.097 | 0.91 | 0.65 to 1.27 | −0.170 | 0.103 | 0.97 | 0.70 to 1.35 |
Among hyperlipidemia patients | ||||||||||||||||
DM (yes/no) | 1.368 | 0.401 | 3.78 | 2.60 to 5.50 | 0.948 | 0.278 | 2.62 | 1.74 to 3.96 | 1.024 | 0.300 | 2.83 | 1.86 to 4.30 | 0.945 | 0.277 | 2.61 | 1.69 to 4.04 |